PHS
IMVT icon

PFM Health Sciences’s Immunovant IMVT Stock Holding History

PFM Health Sciences’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-122,701
Closed -$3.5M – 95
2024
Q3 		$3.5M Sell
122,701
-349,839
-74% -$10.3M 0.2% 58
2024
Q2 		$12.5M Hold
472,540
– – 0.62% 44
2024
Q1 		$15.3M Hold
472,540
– – 0.72% 45
2023
Q4 		$19.9M Hold
472,540
– – 1.19% 30
2023
Q3 		$18.1M Buy
472,540
+83,622
+22% +$1.89M 0.85% 43
2023
Q2 		$7.38M Sell
388,918
-73,513
-16% -$1.37M 0.29% 64
2023
Q1 		$7.17M Buy
+462,431
New +$8.02M 0.32% 61
2020
Q3 		– Sell
-67,163
Closed -$1.64M – 88
2020
Q2 		$1.64M Buy
+67,163
New +$1.44M 0.08% 75

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PFM Health Sciences's IMVT Position: Q4 2024 in Review

PFM Health Sciences sold out of Immunovant (IMVT) in Q4 2024, closing a stake of 122,701 shares — an estimated $3.5M sold.

PFM Health Sciences first reported a position in IMVT in Q2 2020 and held it in 8 quarters. The position peaked at $19.9M in Q4 2023. 186 funds tracked by Wall St. Rank hold IMVT as of Q4 2024.

  • PFM Health Sciences reported no remaining Immunovant position as of Q4 2024 after selling out during the quarter.
  • PFM Health Sciences sold 122,701 Immunovant shares in Q4 2024, an estimated $3.5M.
  • PFM Health Sciences first reported a position in Immunovant in Q2 2020 and held it in 8 quarters.
  • PFM Health Sciences's Immunovant position peaked at $19.9M in Q4 2023.
  • 186 funds tracked by Wall St. Rank held Immunovant as of Q4 2024.

Based on PFM Health Sciences's 13F filing for Q4 2024, filed 14 Feb 2025.